What is Abacavir Sulphate 600mg Tablet Abamune l?
Abacavir Sulphate 600mg Tablet Abamune l is a combination of two antiretrovirals. It is prescribed to treat HIV (human immunodeficiency virus) infection. It boosts up the immunity to fight against HIV to manage or treat AIDS (acquired immunodeficiency syndrome).
How Abacavir Sulphate 600mg Tablet Abamune l is used?
Abacavir Sulphate 600mg Tablet Abamune l will not relieve other side effects associated with cancer treatments. It is administered under the supervision of a healthcare professional and should be taken as advised by the doctor. It is important that you keep having the injections until your doctor decides it is safe to stop them. After taking this, your doctor may prescribe tablets instead of injections.
Common side effects of this Tablet:
The most common side effects of using this Tablet include injection site pain or reaction, headache, constipation, diarrhea, and weakness. These symptoms should disappear when you stop taking the medicine but if they bother you or do not go away, your doctor may be able to suggest ways of preventing or reducing them.
Before Using this medicine, tell your problem to doctor if you have heart or liver problems or a blockage in your stomach or intestines. Also tell your doctor about other drugs you are taking, especially medicines to treat epilepsy, heart problems, cancer, and depression. These may affect, or be affected by, this medicine. If you are pregnant or breastfeeding, ask advice from your healthcare team.
This Injection blocks the action of chemicals in the body that can make you feel or be sick. It is often used to prevent nausea and vomiting that may be caused due to some medicines or cancer treatment. This medicine helps you recover more comfortably from cancer treatments such as radiation therapy or chemotherapy. It is also effective at preventing nausea and vomiting after an operation (in adults only). It is given as an injection by a doctor and should not be self-administered.
Trade Name: ABAMUNE-L
Manufacturer: CIPLA LTD.